Efecto protector del factor de crecimiento de hepatocitos (HGF) en un modelo murino de colestasis
Cholestasis is a condition associated with a full or partial reduction in the bile flow that reaches the duodenum, caused either by a mechanical blockage impeding the normal flow of bile through the intra an d extrahepatic bile ducts (obstructive cholestasis) or due to alterations on the hepatocellu...
| Autor: | |
|---|---|
| Tipo de recurso: | tesis de maestría |
| Estado: | Versión publicada |
| Fecha de publicación: | 2016 |
| País: | México |
| Institución: | Universidad Autónoma Metropolitana |
| Repositorio: | Repositorio Institucional de la UAM Iztapalapa |
| Idioma: | español |
| OAI Identifier: | oai:bindani.izt.uam.mx:0v838060s |
| Acceso en línea: | https://doi.org/10.24275/uami.0v838060s |
| Access Level: | acceso abierto |
| Palabra clave: | info:eu-repo/classification/LEM/Bile -- Diseases -- Treatment info:eu-repo/classification/LEM/Hígado -- Enfermedades -- Tratamiento info:eu-repo/classification/LEM/Bilis -- Enferemedades -- Tratamiento info:eu-repo/classification/LEM/Liver -- Diseases -- Treatment info:eu-repo/classification/cti/2 |
| Sumario: | Cholestasis is a condition associated with a full or partial reduction in the bile flow that reaches the duodenum, caused either by a mechanical blockage impeding the normal flow of bile through the intra an d extrahepatic bile ducts (obstructive cholestasis) or due to alterations on the hepatocellular or ductular mechanisms of bile formation (functional cholestasis). Since it is an often a serious health condition with limited therapeutic options both in number and efficacy, it is necessary to carry out studies with potentially therapeutic molecules that could prevent or co unteract the damage generated by this pathology. Such is the case of hepatocyte growth factor (HGF), a growth factor with powerful antioxid ant, proliferative, anti - apoptotic and motility - stimulating effects, among others. To perform these effects, this growth factor requires activation of many transcription factors, including Nrf2, which regulates, through its target genes, the redox balance within the cell. Cholestasis is a condition associated with a full or partial reduction in the bile flow that reaches the duodenum, caused either by a mechanical blockage impeding the normal flow of bile through the intra - and extrahepatic bile ducts (obstructive cholestasis) or due to alterations on the hepatocellular or ductular mechanisms of bile formation (functional cholestasis). Since it is an often a serious health condition with limited therapeutic options both in number and efficacy, it is necessary to carry out studies with potentially therapeutic molecules that could prevent or co unteract the damage generated by this pathology. Such is the case of hepatocyte growth factor (HGF), a growth factor with powerful antioxid ant, proliferative, anti - apoptotic and motility - stimulating effects, among others. To perform these effects, this growth factor requires activation of many transcription factors, including Nrf2, which regulates, through its target genes, the redox balance within the cell. In this study, we evaluated the ant i - cholestasic capacity of HGF to counteract the damage caused by ANIT (a well-known model of cholestasis), and also the activation of Nrf2 as a putative key factor in the anti - cholesta t ic HGF effect. We o bserved that HGF has clear anti - cholestasic effects, because serum biochemical markers of liver integrity were improved, and liver histological ANIT injury decreased. This could be explained because this growth factor produced an enhancement in the express ion of basolateral and canalicular efflux transporters and of antioxidant enzymes induced by Nrf2. O ur results allow us to propose HGF as a highly efficient anti - cholestasic agent for the first time. |
|---|